Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Insulin glargine (Lantus®)

Brand: Lantus®
Indication: Type 1 and Type 2 diabetes mellitus
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No


Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Insulin glargine 100 units/mL (Lantus®) is recommended for use in patients with type 1 and type 2 diabetes mellitus. Prescribing should be by brand name, followed by the concentration and recommended daily dose. Lantus® brand is not a preferred product in the LMMG antihyperglycaemics guideline Biosimilars of Insulin glargine are also available for the treatment of NEW patients and patients assessed to need a medication change. Treatment should normally be started with the least expensive drug.


LMMG recommendation: Green
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

For biosimilars see Insulin glargine biosimilar (Abasaglar®)

Algorithm For Antihyperglycaemic Therapy In Adults With Type II V1.5 (467.6 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG